Iperion's loss narrows 45% but FY25 again books zero revenue

What changed

Revenue was again $0.0m in FY25, unchanged from FY24, with the company explicitly noting "no sales income in the period". The reported loss narrowed to $0.4m from $0.8m, a 45.3% improvement at both the PBT and NPAT lines (no tax was recognised in either year, so the two measures are identical). Operating cash outflow narrowed to $0.4m from $0.7m, and intangible capex was de minimis at under $0.01m. Cash on hand rose to $0.4m from $0.2m, but total assets fell to $0.5m from $0.9m and equity contracted to $0.4m from $0.8m. No dividend was declared, consistent with FY24.

What matters

• Still a pre-revenue cost base. With FY25 revenue at zero for a second consecutive year, the 45% improvement in the loss is a function of cost reduction rather than commercial traction. The release references an antimicrobial licence agreement with minimum royalty performance targets, but no royalty or sales income has yet been booked.
• Equity erosion is outpacing the cash build. Cash rose by $0.3m, but equity fell by $0.5m and total assets by $0.4m. ROE on the calculation pass weakened to -75.7% from -66.6%, reflecting that the loss, while smaller in dollars, is being absorbed by a smaller capital base.
• Runway is the binding constraint. Against a current-year operating cash burn of $0.4m, the $0.4m closing cash balance implies roughly twelve months of runway at the FY25 burn rate, before any further cost action or capital raise.

Expectations

No quantitative targets, guidance, or forward-work disclosures were provided. The only forward indicator is the reference to minimum royalty performance targets in the antimicrobial licence agreement, but neither thresholds nor timing were disclosed. The HY25 interim showed a $0.4m loss, meaning the second half loss was only about $0.1m — the calculation pass attributes about 82% of the full-year NPAT loss to the first half. That second-half improvement is the most concrete forward signal in the filing, but with revenue still at zero it cannot be read as commercial momentum.

Quality of result

The improvement is durable in the narrow sense that it reflects a lower run-rate cost base rather than a one-off gain — there are no non-recurring items disclosed and no non-GAAP adjustments. Cash conversion is not a meaningful concept here: with no revenue, free cash outflow of $0.4m essentially mirrors the loss (FCF/NPAT ~101%). What the result does not demonstrate is any commercial validation of the licence asset; the entire narrowing is on the cost side. The cash uplift to $0.4m is also not internally generated — operating and investing flows were both negative — so it points to a financing inflow during the year that the supplied excerpts do not detail.

Unresolved

• What was the source of the $0.3m cash increase given operating and capex outflows totalled roughly $0.45m?
• When are the antimicrobial licence's minimum royalty performance targets scheduled to take effect, and what is the contracted minimum value?
• What is the cost trajectory into FY26, and at the current burn does the board contemplate further capital raising before commercial revenue arrives?
• Is the licence asset still carried at a value consistent with no royalty stream having been generated to date?

This briefing cannot assess the technical or commercial viability of the antimicrobial licence, nor any market-based valuation, as neither share price nor NTA per share was supplied.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.